MedTrace Logo

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

NCT04999800 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-08-11

No results posted yet for this study

Summary

This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma with CPS≥1

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer

DRUG

Anlotinib

Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor

Sponsors & Collaborators

  • Shi Yuankai

    lead UNKNOWN

Principal Investigators

  • Yuankai Shi, MD · Cancer Institute/Hospital, Chinese Academy of Medical Sciences&Peking Union Medical college

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-18
Primary Completion
2023-01-01
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999800 on ClinicalTrials.gov